Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sodium oxybate - Jazz Pharmaceuticals

Drug Profile

Sodium oxybate - Jazz Pharmaceuticals

Alternative Names: Gamma-hydroxybutyrate; JZP-6; KEY-10; NSC-84223; Xyrem

Latest Information Update: 10 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jazz Pharmaceuticals
  • Developer Bausch Health Companies; Jazz Pharmaceuticals; Jazz Pharmaceuticals Inc; Jazz Pharmaceuticals plc; UCB
  • Class Butyric acids; Hydroxybutyrates; Sleep disorder therapies; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Narcolepsy; Cataplexy
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cataplexy; Narcolepsy
  • Discontinued Essential tremor; Fibromyalgia

Most Recent Events

  • 25 Jan 2019 Jazz Pharmaceuticals completes the phase II/III EXPRESS trial in Narcolepsy and Cataplexy in Finland, France, Italy, Netherlands, and USA (NCT02221869)
  • 27 Oct 2018 Launched for Narcolepsy (In adolescents, In children) in USA (PO)
  • 26 Oct 2018 Registered for Narcolepsy (In adolescents, In children) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top